Wedbush boosted its price target on Outperform-rated Endocyte (NASDAQ: ECYT) from $16 to $20, or nearly double yesterday's closing price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE